American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 237-240 , February 2010

AURORA: Is There a Role for Statin Therapy in Dialysis Patients?

  • Sabin Shurraw, MD
    • ,
  • Marcello Tonelli, MD, SM

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marcello Tonelli, MD, 7-129 Clinical Science Bldg, 8440 112 St, Edmonton, Alberta T6B 2B7, Canada

References 

  1. US Renal Data System. USRDS 2008 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008;
  2. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–1563
  3. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Trial Study Group Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182
  4. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
  5. Koenig W, Lowel H, Baumert J, Meisinger C. C-Reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349–1353
  6. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-Reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28
  7. Fellstrom BC, Jardine AG, Schmieder RE, et al. AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
  8. Seliger SL, Weiss NS, Gillen DL, et al. HMG-Co A reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297–304
  9. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45(1):119–126
  10. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
  11. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2008;74(11):1461–1467
  12. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125
  13. Wanner C. Statin effects in CKD: is there a “point of no return”?. Am J Kidney Dis. 2009;53(5):723–725
  14. Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol. 2003;14(10):2556–2572
  15. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350–357
  16. London GM, Marchais SJ, Metivier F, Guerin AP. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant. 2000;15(suppl 5):97–104
  17. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261

 Originally published online as doi:10.1053/j.ajkd.2009.09.018 on November 18, 2009.

 No paper or electronic reprints will be available.

PII: S0272-6386(09)01268-2

doi: 10.1053/j.ajkd.2009.09.018

American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 237-240 , February 2010

Article Tools